DIRS.INFO The most relevant business & tech news

He heard at that time that Pfizer's (PFE.N) anti-viral drug Paxlovid was an effective treatment, but patients could only get it prescribed if they were admitted to hospital, and only if the drug was in stock. Li's experience, local media reports and online posts bear testimony to the difficulties faced obtaining Paxlovid in China through official channels. "Pfizer is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China. We remain committed to fulfilling the COVID-19 treatment needs of Chinese patients and partnering with the Chinese government," the company said in a statement. PAXLOVID GIFTSeveral other people described to Reuters how they turned to the grey market to purchase Paxlovid.

☆ Chinese hospital says half of its staff got Covid
▼ + stars: | 2023-01-12 | by ( Evelyn Cheng | ) www.cnbc.com time to read: +3 min

Locals line up for medical treatment at the Beijing Hospital of Traditional Chinese Medicine on June 1, 2022. CFOTO | Future Publishing | Getty ImagesBEIJING — About half of the nearly 2,000 workers at the Beijing Hospital of Traditional Chinese Medicine got Covid-19 during the latest wave, director Liu Qingquan said Wednesday. Liu told reporters the workers all recovered by taking traditional Chinese medicine. China has encouraged the use of traditional Chinese medicine alongside Western treatment for Covid. Rather than pharmaceutical drugs, traditional Chinese medicine relies on herb-based remedies and natural methods to help the body heal itself.

☆ Pfizer CEO says there will be no generic Paxlovid for China
▼ + stars: | 2023-01-10 | by ( ) www.cnbc.com time to read: +1 min

An online pharmacy lists Pfizer's oral anti-Covid drug Paxlovid for 2,980 yuan per box in in Suqian, Jiangsu province, China on Dec. 13, 2022. Pfizer is not in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday. Reuters reported on Friday that China was in talks with Pfizer to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's Covid-19 antiviral drug Paxlovid in China. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market."

☆ Pfizer not in talks on licensing generic COVID pill in China
▼ + stars: | 2023-01-10 | by ( ) www.reuters.com time to read: +1 min

[1/2] Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. A morning and an evening does consists of one white 100-milligram tablet of Ritonavir and two pink 150-milligram tablets of PF-07321332. REUTERS/Wolfgang Rattay/IllustrationNEW YORK, Jan 9 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Albert Bourla said on Monday that the company is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there. Bourla, speaking at J.P. Morgan's healthcare conference in San Francisco, also said that talks with China on future pricing for the treatment had broken off after China had asked for a lower price than Pfizer is charging for most lower middle income countries. "They are the second highest economy in the world and I don't think that they should pay less than El Salvador," Bourla said.

☆ Pfizer working to send COVID pill Paxlovid to China - CNBC
▼ + stars: | 2023-01-09 | by ( ) www.reuters.com time to read: +1 min

Jan 9 (Reuters) - Pfizer Inc (PFE.N) is working with Chinese authorities to send its COVID-19 pill, Paxlovid, to the country that is dealing with a surge in COVID-19 cases, Chief Executive Officer Albert Bourla said in an interview with CNBC on Monday. In February last year, China approved Paxlovid to treat high-risk patients in several provinces. Pfizer has also reached an agreement to export Paxlovid to China through a local company to make the medicine more widely available. China has also been in talks with the drugmaker to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of Paxlovid in China, Reuters reported last week, citing sources. Chinese hospitals have been under intense pressure after the government abruptly abandoned its "zero-COVID" policy last month, sending infections soaring.

☆ Pfizer CEO: 2022 was one of the most successful years in our corporate history
▼ + stars: | 2023-01-09 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO: 2022 was one of the most successful years in our corporate historyCNBC's Meg Tirrell sits down with Pfizer CEO Albert Bourla to discuss the Covid crisis and Pfizer's future in producing 19 new products in the next 18 months.

☆ CIOs Nominate Their Favorite Reads of 2022
▼ + stars: | 2022-12-28 | by ( Tom Loftus | ) www.wsj.com time to read: +9 min

Chief information officers, ever alert to any development in a field that only hurtles forward, largely reflected that alacrity in their choice of reading during 2022. PREVIEWChris Bedi, chief digital information officer, ServiceNow Inc. Photo: IBM Corp.Ron Guerrier, chief information officer, HP Inc. Photo: Cisco Systems Inc.Fletcher Previn, chief information officer, Cisco Systems Inc. Photo: Home Depot Inc.Fahim Siddiqui, chief information officer, Home Depot Inc.

☆ Mike Sievert of T-Mobile is the CNN Business CEO of the Year
▼ + stars: | 2022-12-26 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +8 min

T-Mobile’s solid performance on Wall Street was one big reason why CEO Mike Sievert is the CNN Business pick for CEO of the Year. CNN Business spoke to Sievert about how T-Mobile has continued to perform well in a super competitive business. T-Mobile CEO Mike Sievert talks to employees at a 2022 company event. That has led to higher expenses, but Sievert said T-Mobile is less worried about inflation than other consumer firms. Prepared for more competitionSievert, who has been with T-Mobile since 2012, took over as CEO in 2020 from long-time CEO John Legere.

☆ Fact Check-Pfizer CEO is not resigning and did not say mRNA vaccines 'don’t work'
▼ + stars: | 2022-12-13 | by ( Reuters Fact Check | ) www.reuters.com time to read: +2 min

Social media users in early December 2022 have falsely claimed that Albert Bourla, the CEO of Pfizer, has resigned after allegedly saying that mRNA vaccines are unsafe and ineffective. A Pfizer spokesperson told Reuters via email, “Albert Bourla continues to serve as the chairman and CEO of Pfizer. Multiple studies have shown that mRNA vaccines are safe and effective (here), (here), (here), (here). Pfizer confirmed that CEO Albert Bourla is not resigning. Update Dec. 16, 2022: Updates headline to clarify that Albert Bourla is not resigning and did not say mRNA COVID-19 vaccines don’t work.

☆ FDA expected to decide on Pfizer RSV vaccine for older adults by May 2023
▼ + stars: | 2022-12-07 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The Food and Drug Administration is expected to decide by spring whether to approve Pfizer's vaccine to prevent respiratory syncytial virus, or RSV, in adults ages 60 and older. Pfizer, in a statement Wednesday, said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months. RSV is a common respiratory virus that causes cold like symptoms in most people, but it can result in severe illness in infants and older adults. Between 60,000 and 120,000 older adults are hospitalized with RSV every year and 6,000 to 10,000 older adults die from the virus. Pfizer's vaccine candidate was about 86% effective in preventing severe lower respiratory tract illness, defined as three or more symptoms.

☆ Pfizer/BioNTech say updated Covid-19 booster generates 'substantially higher' protection against Omicron subvariants than original vaccin
▼ + stars: | 2022-11-04 | by ( Jen Christensen | ) edition.cnn.com time to read: +3 min

CNN —Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were “substantially higher” in people who got its new bivalent booster compared with people who received the companies’ original Covid-19 vaccine. The bivalent booster that targets the original coronavirus strain and the Omicron BA.4 and BA.5 subvariants became available in the US in early September. When someone gets any vaccine, it can take a few weeks to build up immunity and generate its full protection. The Omicron BA.5 subvariant had dominated US Covid-19 infections since July, but a mix of other Omicron subvariants have been gaining against it. So far, 26.3 million people age 5 and older in the United States have received updated Covid-19 boosters.

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development should help replace future declining vaccine sales and lost revenue from patent expirations. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns. Third-quarter sales of the COVID vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion. However, $7.51 billion in sales of Paxlovid, the company's COVID-19 antiviral treatment, fell short of estimates of $7.66 billion. Pfizer reported adjusted earnings of $1.78 per share in the third quarter, beating analysts' estimates by 39 cents.

☆ Pfizer boosts COVID vaccine sales forecast by $2 bln
▼ + stars: | 2022-11-01 | by ( Manas Mishra | ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker's shares rose 2.4% to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion.

☆ Pfizer boosts COVID vaccine sales forecast by $2 bln to $34 bln
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker's shares rose 4.3% to $48.55 in premarket trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion, according to five analysts polled by Refinitiv. However, $7.51 billion in sales of the company's COVID-19 pill Paxlovid missed estimates of $7.66 billion.

☆ Pfizer raises sales estimates for COVID vaccine by $2 billion
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised full-year estimates for sales of its COVID-19 vaccine by $2 billion to $34 billion, encouraged by demand for its new Omicron-focused booster shots. The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion. The company reported third-quarter sales of $22.60 billion, beating analysts' estimates of $21.04 billion, according to IBES data from Refinitiv. Third-quarter sales of the COVID-19 vaccine, which Pfizer sells with BioNTech , came in at $4.40 billion, blowing past estimates of $2.60 billion, according to five analysts polled by Refinitiv. However, Paxlovid, the company's pill to reduce the risk of severe COVID-19, brought in sales of $7.51 billion, missing estimates of $7.66 billion.

☆ Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics
▼ + stars: | 2022-11-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Bourla said Pfizer is staring down an expected loss of between $16 billion and $18 billion in revenue from 2025 through 2030 as patent protections for some of its bestselling drugs expire. "We recognize that some are questioning Pfizer's longer-term growth prospects," Bourla told analysts during Pfizer's third-quarter earnings call Tuesday. Taken together, these five drugs represented about 40% of Pfizer's third-quarter revenue this year when the Covid vaccine and the antiviral treatment Paxlovid are excluded. Pfizer's RSV vaccine candidates for older adults and infants have the potential to generate billions in revenue, Bourla said. It would be the only RSV vaccine in the U.S. that protects infants by giving the shot to the mother, he said.

☆ Pfizer raises 2022 earnings guidance, beats third-quarter expectations
▼ + stars: | 2022-11-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Pfizer on Tuesday raised its 2022 earnings guidance after booking a strong third quarter that beat Wall Street expectations. Pfizer raised its full year sales guidance for its Covid-19 vaccine to $34 billion this year, up $2 billion from the company's previous expectations. The company sold $4.4 billion of its Covid vaccine worldwide in the quarter, a decrease of 66% compared to the third-quarter of 2021. Pfizer's antiviral treatment Paxlovid also had a strong quarter, generating $7.5 billion in sales worldwide though mostly in the U.S. Pfizer booked net income of $8.6 billion for the third quarter, a 6% increase over the same quarter last year.

☆ Fact Check-Preventing transmission never required for COVID vaccines’ initial approval; Pfizer vax did reduce transmission of early variants
▼ + stars: | 2022-10-14 | by ( Reuters Fact Check | ) www.reuters.com time to read: +11 min

To get emergency approval, companies needed to show that the vaccines were safe and prevented vaccinated people from getting ill. They did not have to show that the vaccine would also prevent people from spreading the virus to others. Pfizer ‘vaccine’ wasn’t intended to prevent transmission. The newest family of Omicron variants has further eroded vaccine effectiveness against infection and transmission (here) . But even Omicron does not escape vaccine protection completely.

Oct 13 (Reuters) - Pfizer (PFE.N) and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up with human trial data that had previously been missing from their successful filings for regulatory approval. Register now for FREE unlimited access to Reuters.com RegisterThey did not disclose the levels of antibodies generated in the preliminary analysis of the study. Healthcare regulators for the European Union and the United States had already approved the upgraded shot last month, even though trial data from testing on humans had at the time not been available. “While we expect more mature immune response data from the clinical trial of our Omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just one week after vaccination in younger and older adults," said Pfizer Chief Executive Albert Bourla.

☆ Pfizer says omicron shots substantially boosted antibodies against BA.5 subvariant in early human data
▼ + stars: | 2022-10-13 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Pfizer and its German partner BioNTech on Thursday said their new omicron boosters substantially increased protective antibodies against the dominant omicron BA.5 subvariant for adults in the first direct human data released to the public on the new shots. The participants who received the first generation vaccine saw a limited increase in antibodies against BA.5, according to the companies. The early data indicate that the safety profile of the new boosters is the same as the original vaccine, the companies said. The first generation shots were developed only against the first strain of the virus. The FDA authorized the omicron shots without direct human data on how they perform against omicron BA.5, which is causing most infections in the U.S. right now.

☆ Pfizer exec denies CEO negotiated EU COVID vaccine contract via text message
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +1 min

FRANKFURT, Oct 10 (Reuters) - A Pfizer (PFE.N) executive with a lead role in negotiating a COVID-19 vaccine bulk supply agreement with the European Commission "categorically" ruled out that the U.S. drugmaker's chief executive agreed the contract via mobile phone text messages. She added that such talks involve far too many people on both sides and take far too long to be conducted via mobile phone texts. The Commission said in June this year that it no longer had the texts, which later drew criticism from the European Union's ombudswoman. The contract signed last year was the biggest ever sealed for COVID-19 vaccines, with the EU committing to buy 900 million Pfizer-BioNTech (22UAy.DE) shots, with an option to buy another 900 million. Register now for FREE unlimited access to Reuters.com RegisterReporting by Ludwig Burger; Editing by Jan Harvey and Susan FentonOur Standards: The Thomson Reuters Trust Principles.

☆ Pfizer CEO tests positive for COVID for a second time
▼ + stars: | 2022-09-24 | by ( ) www.reuters.com time to read: +2 min

Register now for FREE unlimited access to Reuters.com RegisterAlbert Bourla, CEO of Pfizer attends a discussion at the World Economic Forum (WEF) in Davos, Switzerland May 25, 2022. REUTERS/Arnd WiegmannSept 24 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech (22UAy.DE). A federal health agency said this week that over 25 million doses of the so-called bivalent shots had been sent out. read moreRegister now for FREE unlimited access to Reuters.com RegisterReporting by Mrinmay Dey in Bengaluru; Editing by Daniel WallisOur Standards: The Thomson Reuters Trust Principles.

☆ Pfizer to supply up to 6 mln COVID pill courses for lower income countries
▼ + stars: | 2022-09-22 | by ( ) www.reuters.com time to read: +1 min

Register now for FREE unlimited access to Reuters.com RegisterA 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Pfizer said the supply agreement is part of its strategy to facilitate equitable access to oral COVID treatments. Register now for FREE unlimited access to Reuters.com RegisterThe company has made a deal with several generic drugmakers to produce its treatment at a lower price for developing countries. "This agreement with Global Fund is a critical step that will boost equitable access for high-risk patients in low-and-middle income countries," Chief Executive Officer Albert Bourla said in a statement. Register now for FREE unlimited access to Reuters.com RegisterReporting by Mrinalika Roy in Bengaluru; Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

☆ A treia doză de vaccin Pfizer va fi făcută între 8 si 12 luni de la administrarea celei de-a doua
▼ + stars: | 2021-05-16 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Compania Pfizer a oferit un termen limită pentru administrarea dozei suplimentare de vaccin anti-COVID. CEO-ul Pfizer a spus că a treia doză va fi făcută între 8 si 12 luni de la administrarea celei de a doua, pentru a proteja oamenii de noile mutaţii de coronavirus apărute, scrie Mediafax. În luna aprilie au ajuns la concluzia că cei imunuzați cu vaccinul Pfizer vor avea nevoie, cel mai probabil, de o a treia doză. Pfizer intenţionează să producă 3 miliarde de doze de vaccin pentru coronavirus la nivel mondial pentru 2021 şi 4 miliarde de doze în 2022. Și Moderna va introduce o a treia doză de vaccin, după ce a declarat luna trecută că speră ca până la toamnă să aibă disponibilă doza suplimentară pentru vaccinul anti-Covid pe care îl produce.

Persons: Albert Bourla, digi24 Organizations: Pfizer, Mediafax, UE Locations: SUA, Africa de Sud

☆ Pfizer va introduce a treia doză de vaccin anti-Covid-19
▼ + stars: | 2021-05-16 | by ( Daniela Calmis | ) www.zdg.md time to read: 1 min

Compania Pfizer va introduce a treia doză de vaccin anti-Covid-19. Albert Bourla, CEO-ul companiei producătoare de vaccin, a confirmat pentru prima dată că a treia doză va fi făcută între 8 și 12 luni de la administrarea celei de a doua, transmite Mediafax.ro. Cea de a treia doză de Pfizer va fi administrată pentru a proteja oamenii de noile mutații de coronavirus apărute. În același timp, compania Pfizer are în analiză și un medicament oral experimental pentru tratarea Covid-19, care ar putea fi disponibil în curând. Pfizer intenționează să producă 3 miliarde de doze de vaccin pentru coronavirus la nivel mondial pentru anul 2021 și 4 miliarde de doze în 2022.

Persons: Albert Bourla, Pfizer Organizations: Pfizer

Search resuls for: "Bourla"

25 mentions found